Background and Rationale
Chronic kidney disease (CKD) is a global health problem with an estimated 1 in every 10 people suffering from CKD. Progressive CKD leads to kidney failure, the need for dialysis, increased disability, premature death, and a reduced quality of life. Trials within kidney disease have been inefficient, long and few compared to other internal medicine specialities, which has slowed the discovery of new therapeutics. Some new therapies that slow progression have been identified over the last decade, but gaps remain and data on combinations and synergistic effects of new therapies remains lacking. Therefore, there is an urgent need for high quality evidence-based treatments to address the burden of CKD together with the development and use of efficient trial designs, such as the adaptive platform trial design used in CAPTIVATE.